Café

© 2026 Longbridge｜Terms of Service Privacy Policy

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study | NGEN Stock News

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study | NGEN Stock News

StockTitan

May 25, 2026 at 10:15 PM

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study | NGEN Stock News

NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study | NGEN Stock News

Login to unlock177characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

NervGen Pharma

NGEN.US

Open

--

High

--

Low

--

Prev Close

--

P/E^TTM

--

Market Cap

--

LongbridgeAI